reports
BBSI Opens Nashville Branch Office, Expanding Its Southern Presence
BBSI Opens Nashville Branch Office, Expanding Its Southern Presence VANCOUVER, Wash., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., announced it has opened a physical branch location in Nashville, Tennessee. This expansion further strengthens BBSI’s national presence and underscores the company’s commitment to supporting small and mid-sized businesses across the Southeast. “There’s no better place than Nashville, a c...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored T...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phas...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conf...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM ET Interested pa...
BBSI Earns Fifth Consecutive Great Place To Work® Certification
BBSI Earns Fifth Consecutive Great Place To Work® Certification VANCOUVER, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., is proud to announce that for the fifth year in a row, the company has been Certified™ by Great Place To Work®. This prestigious award is based entirely on what current employees say about their experience working at BBSI. “We are honored to be recognized as a Great Place To Work for the fi...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcar...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025. Details of the presentation can be found below. Presenters: Mark Erlander, PhD (CEO) Date: 12/02/2025...
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launc...
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to-head data continue to be favorablePreparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results: ...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Busin...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to de...
BBSI Reports Third Quarter 2025 Financial Results
BBSI Reports Third Quarter 2025 Financial Results - Revenues up 8% to $318.9 Million and Gross Billings up 9% to $2.32 Billion - VANCOUVER, Wash., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Year-Ago Quarter Revenues up 8% to $318.9 million.Gross billings up 9% to $2.32 billion.Average worksite employees (“WSEs”) up 6%.Net income increased to $20.6 million...
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025. Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO) Date: 11/11/2025Time: 9:30 AM ET Stifel 2025 Healthcare ConferenceFo...
iMDx to Release Third Quarter 2025 Results on November 10 and Attend S...
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the fo...
BBSI Sets Third Quarter 2025 Conference Call for Wednesday, November 5...
BBSI Sets Third Quarter 2025 Conference Call for Wednesday, November 5, 2025, at 5:00 p.m. ET VANCOUVER, Wash., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., will conduct a conference call on Wednesday, November 5, 2025, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss its financial results for the third quarter ended September 30, 2025. The company will report its financial results in a press release prio...
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant As...
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team as the company prepares to launch its first clinical kitted assay in 2026. As Vice ...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with No...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve patient’s immune systemAs transplant care evolves to include novel therapies, the need for ongoing molecular diagnostic monitoring should continue to grow NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasd...
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)Date: 10/09/2025Time:...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transpl...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced...
Insight Molecular Diagnostics Announces Positive Strategic Update and ...
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database 5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA)Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one scoreRegistry expected to assess utility of “the Berlin protocol” of accelerated...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcome...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, now names 10 leading transpl...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below. Wells Fargo 20th Annual Healthcare Conference Format: 1x1 Meetings Date: 09/05/2025Location: Encore Boston Harbor, Everett, MA Morgan Stanley 23rd Annual Gl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.